MS and Demyelinating Disorders

Neurology News Network for the week ending February 22, 2020.

New data suggest a switch from natalizumab to a high efficacy disease-modifying therapy for patients with multiple sclerosis is more beneficial than switching to moderate efficacy therapy, including a lower risk of disease activity.

The Prometra II offers a pressure-driven, valve-gated delivery mechanism that allows for novel programming modes of intermittent flow followed by periods of no flow—a feature unique to this device.

Neurology News Network for the week ending February 15, 2020.

Neurofilament light chain has emerged as a biomarker with utility across the breadth of neurology, but just how much can it actually help?

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Daniel Hartung, PharmD, MPH.

The antioxidants adiponectin, total radical-trapping antioxidant parameter, sulfhydryl groups, zinc, and soluble tumor necrosis factor receptor 2 all play a role in the pathophysiology of multiple sclerosis.

New retrospective data suggest that patients with MS who have comorbid conditions have increased all-cause hospital admission rates, especially early in the disease.

Sanofi observed a dose-response relationship based on reduction of new active gadolinium-enhancing T1-hyperintense lesions after 12 weeks of treatment with SAR442168.

The software, developed by Qynapse, provides analysis of brain MRI markers in diseases such as Alzheimer disease, Parkinson disease, and multiple sclerosis.